Chinese biotech firm I-Mab launches $111m US listing

Nasdaq_alamy_230x150
By Jonathan Breen
06 Jan 2020

I-Mab, a China-based biopharmaceutical company, has kicked off the roadshow for its up to $111.1m Nasdaq IPO, more than two months after filing draft documents with the US regulator.

CICC and Jefferies are leading the sale of American Depository Shares (ADS), and have begun bookbuilding for the deal. China Renaissance and Huatai Securities (USA) are the junior members of the syndicate.

The float comprises 7.4m ADS, with every 10 representing 23 of the company’s ordinary shares, or ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.